As of 2025-10-19, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is 0.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is -2.40 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-10-16 | 0.04 |
| 2025-10-15 | 0.04 |
| 2025-10-14 | 0.02 |
| 2025-10-13 | 0.03 |
| 2025-10-10 | 0.04 |
| 2025-10-09 | 0.02 |
| 2025-10-08 | 0.01 |
| 2025-10-07 | 0.00 |
| 2025-10-06 | 0.02 |
| 2025-10-03 | 0.02 |
| 2025-10-02 | 0.02 |
| 2025-10-01 | 0.05 |
| 2025-09-30 | 0.02 |
| 2025-09-29 | -0.06 |
| 2025-09-26 | -2.86 |
| 2025-09-25 | -2.73 |
| 2025-09-24 | -2.88 |
| 2025-09-23 | -2.51 |
| 2025-09-22 | -2.78 |
| 2025-09-19 | -2.96 |
| 2025-09-18 | -2.61 |
| 2025-09-17 | -2.60 |
| 2025-09-16 | -2.74 |
| 2025-09-15 | -2.90 |
| 2025-09-12 | -2.79 |
| 2025-09-11 | -2.53 |
| 2025-09-10 | -2.24 |
| 2025-09-09 | -2.03 |
| 2025-09-08 | -2.11 |
| 2025-09-05 | -2.12 |
| 2025-09-04 | -2.12 |
| 2025-09-03 | -2.20 |
| 2025-09-02 | -1.73 |
| 2025-08-29 | -1.58 |
| 2025-08-28 | -1.47 |
| 2025-08-27 | -1.32 |
| 2025-08-26 | -1.26 |
| 2025-08-25 | -1.17 |
| 2025-08-22 | -1.24 |
| 2025-08-21 | -1.13 |
| 2025-08-20 | -1.10 |
| 2025-08-19 | -1.11 |
| 2025-08-18 | -1.14 |
| 2025-08-15 | -1.10 |
| 2025-08-14 | -1.06 |
| 2025-08-13 | -1.02 |
| 2025-08-12 | -0.95 |
| 2025-08-11 | -0.91 |
| 2025-08-08 | -0.94 |
| 2025-08-07 | -0.91 |